No Data
Foghorn Therapeutics Shares Are Trading Higher After the Company Reported Better-than-expected Q3 EPS Results.
H.C. Wainwright Maintains Foghorn Therapeutics(FHTX.US) With Buy Rating, Maintains Target Price $20
TD Cowen Maintains Foghorn Therapeutics(FHTX.US) With Buy Rating
TD Cowen Keeps Their Buy Rating on Foghorn Therapeutics (FHTX)
Foghorn Therapeutics Inc. (FHTX) Reports Q3 Loss, Misses Revenue Estimates
Express News | Foghorn Therapeutics Inc.: Cash, Cash Equivalents, and Marketable Securities of $267.4 Mln as of September 30, 2024, Provides Cash Runway Into 2027
No Data
No Data